RNXT – renovorx, inc. (US:NASDAQ)
Stock Stats
News
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026 [Yahoo! Finance]
RenovoRx Announces Acceptance of Clinical Data Abstract at the ASCO Gastrointestinal Cancers Symposium 2026
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Winter Investment Conference 2025 on December 9th
RenovoRx (NASDAQ:RNXT) had its "sell (e+)" rating reaffirmed by analysts at Weiss Ratings.
RenovoRx (NASDAQ:RNXT) had its price target raised by analysts at Ascendiant Capital Markets from $12.00 to $12.50. They now have a "buy" rating on the stock.
Form 4 RenovoRx, Inc. For: Dec 05 Filed by: Agah Ramtin
Form 4 RenovoRx, Inc. For: Nov 21 Filed by: Agah Ramtin
Form 8-K RenovoRx, Inc. For: Nov 14
Form 424B5 RenovoRx, Inc.
Form S-3 RenovoRx, Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.